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Abstract
Type 2 diabetes (T2D) imposes a heavy public health burden in both developed and developing countries. It is necessary to
understand the effect of T2D in different settings and population groups. This report aimed to present baseline characteristics of
study participants in the demonstration area for the “Type 2 Diabetes Prevention in Barranquilla and JuanMina” (DEMOJUAN) project
after randomization and to compare their fasting and 2-hour glucose levels according to lifestyle and T2D risk factor levels.
The DEMOJUAN project is a randomized controlled ﬁeld trial. Study participants were recruited from study sites using population-
wide screening using the Finnish Diabetes Risk Score (FINDRISC) questionnaire. All volunteers with FINDRISC of ≥13 points were
invited to undergo an oral glucose tolerance test (OGTT). Participant inclusion criteria for the upcoming ﬁeld trial were either FINDRISC
of ≥13 points and 2-hour post-challenge glucose level of 7.0 to 11.0mmol/L or FINDRISC of ≥13 points and fasting plasma glucose
level of 6.1 to 6.9mmol/L. Lifestyle habits and risk factors for T2D were assessed by trained interviewers using a validated
questionnaire.
Among the 14,193 participants who completed the FINDRISC questionnaire, 35% (n=4915) had a FINDRISC score of ≥13 points
and 47% (n=2306) agreed to undergo the OGTT. Approximately, 33% (n=772) of participants underwent the OGTT and met the
entry criteria; these participants were randomized into 3 groups. There were no statistically signiﬁcant differences found in
anthropometric or lifestyle risk factors, distribution of the glucose metabolism categories, or other diabetes risk factors between the 3
groups (P> .05). Women with a past history of hyperglycaemia had signiﬁcantly higher fasting glucose levels than those without
previous hyperglycaemia (103 vs 99mg/dL; P< .05).
Lifestyle habits and risk factors were evenly distributed among the 3 study groups. No differences were found in fasting or 2-hour
glucose levels among different lifestyle or risk factor categories with the exception of body mass index, past history of
hyperglycaemia, and age of ≥64 years in women.
Trial registration: NCT01296100 (2/12/2011; Clinical trials.gov).
Abbreviations: FPG = fasting plasma glucose, IFG = impaired fasting glucose, IGT = impaired glucose tolerance, OGTT = oral
glucose tolerance test, T2D = type 2 diabetes.
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Type 2 diabetes (T2D) imposes a heavy public health burden in
both developed and developing countries.[1] The growing
prevalence of T2D with its high morbidity and mortality will
impose a heavy burden on healthcare systems.[2] The predicted
number of diagnosed T2D patients will increase in Latin America
and a large number of asymptomatic cases of T2D will remain
undiagnosed. This is problematic, as asymptomatic T2D is
associated with 2-fold and impaired glucose tolerance (IGT) with
1.4-fold increased mortality.[3]
People with a positive family history of diabetes mellitus have a
higher likelihood of developing T2D once exposed to a lifestyle
that enhances obesity (unhealthy diet and physical inactivity).[4–6]
The treatment of T2D is difﬁcult and regardless of pharmaco-
logical treatment, blood glucose levels have been shown to
increase over time.[7] Therefore, primary T2D prevention
strategies may be more efﬁcient than secondary prevention
approaches. In addition, the most common T2D complications
(e.g., cardiovascular diseases) may be postponed by preventing
the development of T2D, highlighting the importance of early
T2D prevention in the susceptible population.
There is a growing body of evidence suggesting that T2D can
be prevented or at least delayed. Early studies in Finland and the
USA revealed that nutritional and physical activity interventions
can decrease the relative risk of T2D up to 58% in people with
IGT.[8,9]
While these ﬁndings offer a compelling evidence base, it is
necessary to understand how the prevention of T2D works in
different settings and population groups. In addition, it is
important to determine the extent to which each component (e.g.,
nutrition, physical activity, nutrition/physical activity) of lifestyle
interventions works best in the prevention of T2D in Latin
America, and especially in the Caribbean region. For instance, it
has been clearly shown that each component (nutrition, physical
activity) of lifestyle interventions either separately[10] or
combined[8–13] has successfully decreased the risk of T2D in
people with IGT. Thus far, such trials have not been conducted in
the Caribbean region and it is unclear whether these lifestyle
changes are effective in a hot, humid climate. This is particularly
true for the physical activity component. The aim of this report is
to present baseline characteristics of study participants in the
demonstration area for the “Type 2 Diabetes Prevention in
Barranquilla and Juan Mina” (DEMOJUAN) project after
randomization to groups and to compare their fasting and 2-
hour glucose levels according to lifestyle and T2D risk factor
levels.2. Methods
2.1. Design and sample size calculations
The study design of the DEMOJUAN project is a randomized
controlled ﬁeld trial. The main objective of the DEMOJUAN
project is to investigate to what extent it is possible to reach
normal glucose metabolism and optimal cardiovascular disease
risk factor levels with early lifestyle interventions in people at
high risk of T2D compared with those who receive standard
therapy (usual care) only. Finally, this project will examine the
effect of these interventions, for the ﬁrst time, in people of low
socio-economic levels living in a Caribbean environment. This
study may provide important information and experiences for
policy making and planning of primary prevention activities not
only in the local healthcare system but in the entire Caribbean2region. The current report presents the results of the baseline
assessment and participant recruitment process using a cross-
sectional design.
The study was designed to have 90% power to detect a 20%
unit difference in recovery from IGT (comparing 70% vs 50%
recovery rates) between the treatment groups at a 5% signiﬁcance
level. Assuming a loss to follow-up of 30% at the end of the 24-
month intervention, a total of 200 participants were needed in
each treatment group (i.e., total sample size of 600 individuals).
The drop-out rate of 30% was estimated according to the results
and experiences of previous randomized controlled diabetes trials
in translational research.[14,15] In addition, this sample size
provides >90% power to detect a 6-mmHg difference in change
in systolic blood pressure (standard deviation [SD]=14mmHg)
between the treatment groups with a 5% signiﬁcance level.2.2. Screening for study participants
Study participants were recruited from the study sites (JuanMina
and Barranquilla) by population-wide screening using the Finnish
Diabetes Risk Score (FINDRISC).[14–16] The study sites have
approximately 1,000,000 inhabitants. FINDRISC is based on
easily attainable information using 8 parameters with categorized
answers. The total risk score ranges from 0 to 26. FINDRISC was
shown to predict the 10-year risk of drug-treated T2D with a
sensitivity of 78% to 81% and a speciﬁcity of 76% to 77%.[14]
Furthermore, it also detects reasonably prevalent asymptomatic
T2D and other disorders of glucose metabolism.[17] FINDRISC
has been validated in many populations with good results[18–23]
and has been successfully applied in primary care in Barcelona,
Spain.[21] It is recommended as a screening tool for T2D by the
International Diabetes Federation and in the guidelines of the
European Society for the Study of Diabetes and the European
Society of Cardiology.[22,24] In the current study, all volunteers
with a FINDRISC score of ≥13 were invited to undergo an oral
glucose tolerance test (OGTT). Participant inclusion criteria for
the upcoming ﬁeld trial were either FINDRISC of ≥13 points and
2-hour post-challenge glucose level of 7.0 to 11.0mmol/L or
FINDRISC of ≥13 points and fasting plasma glucose level of 6.1
to 6.9mmol/L.
If a study participant met the inclusion criteria and agreed to
participate, he/she was randomized into 1 of 3 groups (A, B, or
C). Sequences for the random allocation groups were generated
by IBM SPSS Statistics forWindows (Version 19.0. Armonk, NY:
IBM Corp.). This study followed the Good Clinical Practice
guidelines and the guidelines of the Helsinki Declaration. All data
have been collected using previously tested questionnaires and
methods as much as possible. Besides blood samples, no invasive
methods were used. The study protocol was approved by the
Research Ethics Committee of the University Pontiﬁcia Javeriana,
Bogota, Colombia. All participants gave their written informed
consent prior to participation to the study.3. Non-invasive measurements
Lifestyle habits and risk factors for T2D were assessed by an
interview using a questionnaire consisting of information
regarding sociodemographic factors, history of T2D, medical
history, tobacco consumption, hypertension, and nutritional and
physical activity habits. The instruments applied were designed
based on FINDRISC, the STEPwise approach to surveillance and
the International Physical Activity Questionnaire (IPAQ),[25–30]
all of which have been previously successfully validated in large
[25–31]
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questionnaire used herein (IPAQ) shows a high correlation with
physical ﬁtness, measured by maximal oxygen uptake.[32,33]
Dietary habits were assessed via 16 questions (e.g., dietary
pattern, quality and quantity of dietary fat, consumption of fruit
and vegetables, grain, milk, and meat products, desserts, sweets,
and alcoholic beverages). In addition, 6 questions were related to
perceived need and intentions to make dietary changes. Scientiﬁc
validation of the dietary questionnaire is ongoing in the National
Institute for Health and Welfare in Helsinki, Finland.
Participant height and weight were measured without shoes
and wearing light clothing. Body mass index (BMI) was
calculated as weight (kg) divided by height squared (m2). Waist
circumference (to the nearest cm) was measured at the
approximate midpoint between the lower margin of the last
palpable rib and the top of the iliac crest. Blood pressure
(precision=2mmHg) was recorded twice using a mercury
sphygmomanometer while study participants were in a seated
position.4. Biochemical measurements
All participants underwent an OGTT that was conducted
according to the World Health Organization recommenda-
tions.[34] The test was conducted after fasting for 12hours, and
fasting and 2-hour blood samples were obtained after oral
ingestion of a water solution with 75g of anhydrous glucose.
Glucose tolerance status was classiﬁed according to the criteria of
the American Diabetes Association.[35] Participants with a fasting
plasma glucose (FPG) level of ≥126mg/dL or a 2-hour plasmaAssessed fo
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3glucose (2hPG) level of ≥200mg/dL were classiﬁed as having
T2D. Those with 2hPG of ≥140mg/dL but<200mg/dL and FPG
of <100mg/dL were classiﬁed as having isolated IGT. Isolated
impaired fasting glucose (IFG) was deﬁned as FPG of ≥100 but
<126mg/dL and 2hPG of <140mg/dL. Participants with 2hPG
of ≥140mg/dL but <200mg/dL and FPG of ≥100 but <126mg/
dL were deﬁned as having combined IGT and IFG. Finally, those
with T2D, IGT, or IFG were classiﬁed as having impaired glucose
regulation.5. Statistical analysis
Data were analyzed using IBM SPSS Statistics for Windows.
Variables were checked for normality using Kolmogorov–
Smirnoff tests. The chi-squared test was used to test for
differences in the distribution between categorized variables.
The independent t test for normally distributed variables and the
Mann–Whitney U test for non-normally distributed variables,
respectively, were used to test for differences in continuous
variables between men and women. Differences in continuous
variables between ≥3 groups were assessed using analysis of
variance. Results are expressed as percentages, means and
standard errors or SDs. The threshold for statistical signiﬁcance
was set at P< .05.6. Results
Figure 1 presents the ﬂow chart of participant recruitment of the
DEMOJUAN project. In total, 14,193 participants completed the
FINDRISC questionnaire during participant screening activitiesr eligibility 
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cruitment for the DEMOJUAN project.
Table 1
Baseline characteristics of the study participants.
Intervention groups
Control (n=246) Nutrition (n=261) Physical activity (n=265)
Mean (SD) Mean (SD) Mean (SD) P value
Age 54 (9) 53 (9) 52 (8) .105
BMI 30.08 (5.06) 29.76 (5.49) 30.29 (5.41) .511
Waist circumference 101.4 (10.9) 101.2 (10.9) 101.2 (11.6) .982
FINDRISC 16 (0.2) 16 (0.2) 16 (0.2) .663
% (n) % (n)
>30min physical activity/d 13 (31) 13 (35) 15 (40) .703
Daily consumption of fruits and vegetables 23 (57) 20 (51) 23 (61) .528
Anti-hypertension drug use 46 (114) 44 (115) 46 (121) .868
Family history of diabetes 71 (175) 77 (200) 75 (198) .648
Previous increased glucose in blood 28 (69) 30 (77) 35 (93) .187
Baseline characteristics of the study participants recruited within the framework of the DEMOJUAN project in Barranquilla, Colombia. BMI=body mass index; FINDRISC= Finnish Diabetes Risk Score.
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FINDRISC of ≥13 points and 47% (n=2306) agreed to undergo
the OGTT. Approximately, 33% (n=772) of participants
underwent the OGTT and met the entry criteria; these
participants were then randomized into 3 groups. The control
group (A) comprised of 246 participants, the nutritional/physical
activity intervention group (B) comprised of 261 participants,
and the physical activity/nutrition group (C) comprised of 265
participants.
Participant characteristics at baseline are shown in Table 1.
There was no statistically signiﬁcant difference found in
anthropometric, lifestyle, or other diabetes risk factors between
the 3 groups (P> .05 for all). The mean FINDRISC was 16
points, with no statistically signiﬁcant differences between groups
(P= .663).
Table 2 shows the prevalence of glucose metabolism
disorders between the 3 groups. No statistically signiﬁcant
difference in the distribution of glucose metabolism
categories was observed between groups in the bivariate analysis
(P= .069).
Table 3 presents participants’mean fasting and 2-hour glucose
levels according to lifestyle habits and risk factors of T2D.
Women with a past history of hyperglycaemia had signiﬁcantly
higher fasting glucose levels compared with those without
previous hyperglycaemia (mean=103 vs 99mg/dL; P< .05). In
addition, women with a BMI of >30kg/m2 had higher fasting
glucose levels compared with those with a normal BMI. Finally,
women in the oldest age group (>64 years) had signiﬁcantly
higher 2-hour glucose levels (mean=152mg/dL) compared
with younger age groups (P< .05). No statistically signiﬁcantTable 2
Categories of disturbances of glucose metabolism in participants in
Interven
Control group Nutr
% (n) %
Normoglycemia 18 (22) 11
Isolated IFG 32 (40) 28
Isolated IGT 35 (44) 41
IFG and IGT 15 (19) 20
Type 2 diabetes 0 (0) 0
Baseline characteristics of the study participants recruited within the framework of the DEMOJUAN pro
4differences were found in men in regard to fasting or 2-hour
glucose levels between different categories of lifestyle habits or
risk factors of T2D.7. Discussion
7.1. Screening and baseline characteristics of study
participants
Up-to-date information regarding compliance with instructions
to undergo an OGTT after a positive screening test is scant.
Although Davies and Day[36] reported compliance of 93%
following a positive screening test in Great Britain, in our project,
only approximately half of high-risk individuals invited to an
OGTT appeared at the laboratory.[37] Furthermore, in the
European Diabetes Prevention Study (EDIPS), only 66% of
participants invited to be screened using an OGTT appeared at
the laboratory for blood extractions.[38] One possible reason for
lower compliance may be related to time constraints, as the
OGTT requires a visit to the laboratory in the morning and lasts
at least 2hours, which may be difﬁcult to arrange for people
working during the daytime. A possible explanation for the
difference in the ﬁndings between our and the British study may
be accessibility to a laboratory and the fact that access to/
availability of public transportation surely differs between
Barranquilla (Colombia) and Western Europe. Therefore, a
future challenge will be to develop strategies to motivate
individuals identiﬁed as being at a high risk of T2D to attend
the laboratory test to conﬁrm their diagnosis. Implementing
simpler ways to test blood glucose levels, such as the recently2011 according to the intervention group.
tion group
ition Physical activity
(n) % (n) P value
(15) 13 (17) .069
(57) 23 (38)
(38) 29 (30)
(28) 35 (47)
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ject in Barranquilla, Colombia. IFG= impaired fasting glucose, IGT= impaired glucose tolerance.
Table 3
Mean fasting and 2-hour glucose levels according to lifestyle habits and risk factors of type 2 diabetes in the study participants.
Men Women Total
Fasting glucose 2-h glucose Fasting glucose 2-h glucose Fasting glucose 2-h glucose
Age group
<45 y 98 (3) 142 (6) 99 (1) 142 (2) 99 (1) 142 (2)
45–54 y 102 (2) 139 (4) 101 (1) 141 (2) 101 (1) 141 (2)
55–64 y 99 (2) 146 (4) 100 (1) 143 (2) 100 (1) 143 (2)
>64 y 96 (3) 142 (6) 100 (1) 152 (3)† 100 (1) 151 (3)†
BMI
∗
<25kg/m2 101 (3) 142 (7) 98 (1) 143 (3) 98 (1) 143 (3)
25–30kg/m2 100 (2) 139 (4) 100 (1) 141 (2) 100 (1) 141 (1)
>30kg/m2 98 (2) 146 (3) 101 (1)‡ 145 (1) 101 (1) 145 (1)
Waist circumference
<94cm (men)/<90cm (women) 107 (5) 129 (10) 96 (3) 154 (7) 101 (3) 144 (6)
≥94cm (men)/≥90cm (women) 98 (2) 142 (4) 98 (2) 147 (3) 98 (1) 145 (3)
100 (1) 144 (3) 101 (1) 143 (1) 100 (1) 143 (1)
Physical activity
<30min physical activity/d 96 (3) 152 (8) 100 (1) 143 (3) 99 (1) 145 (3)
≥30min physical activity/d 100 (1) 140 (2) 100 (1) 143 (1) 100 (1) 143 (1)
Past history of hyperglycemia
No 99 (1) 143 (3) 99 (1) 142 (1) 99 (1) 142 (1)
Yes 101 (2) 141 (4) 103 (1)x 146 (2) 103 (1)x 145 (2)
Family history of diabetes mellitus
No 97 (2) 141 (5) 101 (1) 145 (2) 100 (1) 144 (2)
Yes: grandparent, uncle, aunt, or cousin 97 (2) 143 (5) 100 (1) 141 (2) 99 (1) 141 (2)
Yes: biological father, mother, or sibling 102 (2) 142 (3) 100 (1) 144 (1) 101 (1) 143 (1)
∗
Body mass index.
† P value <.05 compared with all other groups.
‡ P value <.05 compared with <25kg/m2 group.
x P value <.05.
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improve treatment compliance.[39]
The baseline characteristics of our study sample in regard to
fasting and 2-hour glucose levels were different compared with
previous randomized clinical trials in individuals with glucose
intolerance.[10,11,13,38,40–42] The 2-hour glucose levels reported in
previous studies were approximately 160mg/dL,[10,11,13,34,40–42]
whereas the post-prandial glucose levels in our study participants
were almost 15mg/dL lower. Moreover, fasting glucose levels of
participants at baseline in previous clinical trials were higher than
those in our participants, with the exception of the DaQing study
population.[10] Further, whereas study participants of lifestyle
intervention trials conducted in Asian populations[10,11,42] had a
lower baseline waist circumference and BMI, those of our study
participants were similar to those of the 2 European studies.[13,41]
The participants of the US Diabetes Prevention Program and
EDIPS-Newcastle[38,40] had a remarkably higher BMI and waist
circumference at baseline than those observed in our study. In
addition, whereas 7 out of 10 participants in our study had a
positive family history of diabetes, only 1 out of 4 had family
members with diabetes in a Japanese trial.[42] Finally, the Asian
studies included participants with a lower mean age than did
most other previous clinical lifestyle intervention trials.[10,11,42]7.2. Description of upcoming lifestyle interventions
During the following 24 months, the control group (A) will
receive standard treatment (usual care: lifestyle advice prescribed
by his/her physician). The 2 intervention groups (B and C) will
receive early, intensive lifestyle interventions. Group B will
receive a 6-month nutritional intervention followed by a 6-month
physical activity intervention and ﬁnally a 12-month combined5nutritional and physical activity intervention. Group B will also
receive individual advice about how to achieve the intervention
goals, which are as follows: reduction in weight of ≥5%; total fat
intake of <30% of energy consumed; saturated fat intake of
<10%of energy consumed, and fruit or vegetable intake of≥500
g per day. Group C will begin with the 6-month physical activity
intervention followed by the 6-month nutritional intervention.
The physical activity intervention consists of individual visits
with a physical activity specialist and monthly group seminars.
Speciﬁcally, each participant will have 6 individual visits with a
physical activity specialist (4 times during the ﬁrst year and twice
in the second year) in which they will receive an individual
physical activity prescription. The goal of the physical activity
intervention is to practice moderate-intensity exercise for ≥30
min/d. In addition, Group B and C participants will attend group
seminars in groups of 10 participants. Group seminars will be
held monthly during the ﬁrst 12 months of the intervention and
then every second month during the second year of the
intervention. Group seminars will be led by a nutritionist and
physical activity specialist.
Finally, in order to reduce the possibility of bias due to the visit
schedule, both intervention groups will undergo their group
sessions and individual visits in parallel. Another possible bias
that will be more difﬁcult to control for is the Hawthorne (i.e.,
observer) effect. As participants in the control group will be
aware that they are at increased risk of T2D and that they are
taking part in a T2D prevention study, they may change their
lifestyles due to the fact that they are under supervision.
However, the Hawthorn effect is reduced with longer interven-
tion programme duration. Our intervention will last for 24
months and may thus be long enough to reduce the bias of the
Hawthorne effect.
[15] Costa B, Barrio F, Cabré JJ, et al. DE-PLAN-CAT Research Group-
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This baseline assessment of participants in the DEMOJUAN
project revealed that it is possible to recruit individuals at risk of
T2D for a ﬁeld trial using a simple screening tool in a population
of a country in economic transition such as Colombia. The
randomization process revealed that lifestyle habits and risk
factors were distributed evenly among the 3 study groups. No
differences were found in fasting or 2-hour glucose levels among
the various lifestyle or risk factor categories, with the exception of
BMI, past history of hyperglycaemia and age >64 years in
women.
As the participants in our study had lower fasting and 2-hour
glucose levels at baseline compared with those of the previous
trials mentioned above, the upcoming interventions will show to
what extent normoglycaemia can be achieved, even in individuals
with a more favorable glucose proﬁle.9. Authors’ contributions
TA, NCB, and JT planned the study, analyzed the data and wrote
the report. AA and CR reviewed the manuscript and assisted in
statistical analysis and results interpretation.References
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